10.21147/j.issn.1000-9604.2017.05.04
A phase Ⅰ study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia
29
The authors would like to thank all the investigators and patients who participated in this study.This work was supported by Hangzhou Jiuyuan Gene Engineering Co.,Ltd,and partly funded by the Chinese National Science and Technology Major Project on Key New Drug Creation2012ZX09303-012;Beijing Municipal Science & Technology Commission Major Project for New Drug InnovationZ111102071011001;China
2018-06-19(万方平台首次上网日期,不代表论文的发表时间)
共9页
402-410